|
|
|
Volumn 60 Suppl 7, Issue , 2009, Pages 67-70
|
|
How to improve the safety of biologic therapy in Crohn's disease.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
GASTROINTESTINAL AGENT;
IMMUNOLOGIC FACTOR;
IMMUNOSUPPRESSIVE AGENT;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
NONSTEROID ANTIINFLAMMATORY AGENT;
TUMOR NECROSIS FACTOR ALPHA;
CROHN DISEASE;
DRUG ANTAGONISM;
DRUG CONTRAINDICATION;
DRUG HYPERSENSITIVITY;
FEMALE;
HUMAN;
IMMUNOLOGY;
LATENT TUBERCULOSIS;
MALE;
MORTALITY;
NEOPLASM;
OPPORTUNISTIC INFECTION;
PREGNANCY;
REVIEW;
VACCINATION;
ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL;
ANTIBODIES, MONOCLONAL;
CROHN DISEASE;
DRUG HYPERSENSITIVITY;
FEMALE;
GASTROINTESTINAL AGENTS;
HUMANS;
IMMUNOLOGIC FACTORS;
IMMUNOSUPPRESSIVE AGENTS;
LATENT TUBERCULOSIS;
MALE;
NEOPLASMS;
OPPORTUNISTIC INFECTIONS;
PREGNANCY;
TUMOR NECROSIS FACTOR-ALPHA;
VACCINATION;
|
|
EID: 77955872495
PISSN: None
EISSN: 18991505
Source Type: Journal
DOI: None Document Type: Review |
|
Times cited : (24)
|
|
References (24)
|
